PRKAA2 and atrial fibrillation: The meaning of our study should be limited in the effect of irbesartan on inflammatory response and the AMPK signaling, but not in clinical parameters of AF patients, such as reducing cardiovascular events, hospitalization, and first episode of recurrence.